oncolytic virus

U turn turn around refocus pivot street sign
Biotech

Theriva prioritizes oncolytic adenovirus at expense of GvHD drug

Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change up in its R&D focus.
Ben Adams Mar 7, 2025 4:47am
pass the torch deal sell buy acquisition

4 years on from launch, IconOVir sells oncolytic virus to UroGen

Feb 20, 2025 9:12am
Wall Street stock exchange finance shares share price Nasdaq

Candel burns bright as phase 3 cancer win sends stock up 200%

Dec 11, 2024 9:49am
Graphic showing arrows missing the bullseye on a target

Transgene's viral cancer vaccine flunks midphase test

Oct 14, 2024 4:59am
one white and yellow capsule farther ahead than four other same-colored blue capsules

CG sets new bar in bladder cancer, months after huge IPO

May 3, 2024 11:23am
icy water dive polar plunge cold thaw arctic ice freezing

CG Oncology plans IPO ahead of phase 3 bladder cancer readout

Jan 3, 2024 8:25am